Cellectar Biosciences (NASDAQ:CLRB) Price Target Raised to $28.00 at Roth Mkm

Cellectar Biosciences (NASDAQ:CLRBFree Report) had its target price hoisted by Roth Mkm from $20.00 to $28.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on CLRB. StockNews.com upgraded Cellectar Biosciences to a sell rating in a report on Thursday, December 28th. Oppenheimer restated an outperform rating and issued a $12.00 price target (up from $11.00) on shares of Cellectar Biosciences in a report on Thursday.

Read Our Latest Stock Report on CLRB

Cellectar Biosciences Trading Up 9.5 %

CLRB stock opened at $3.98 on Thursday. The business’s 50-day moving average price is $3.68 and its two-hundred day moving average price is $2.95. Cellectar Biosciences has a 1-year low of $1.30 and a 1-year high of $4.45.

Institutional Trading of Cellectar Biosciences

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Cellectar Biosciences by 2.3% in the third quarter. Vanguard Group Inc. now owns 175,884 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 3,911 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Cellectar Biosciences by 11.5% in the second quarter. Renaissance Technologies LLC now owns 63,990 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 6,589 shares during the last quarter. State Street Corp increased its position in shares of Cellectar Biosciences by 4.5% in the second quarter. State Street Corp now owns 157,146 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 6,800 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of Cellectar Biosciences in the fourth quarter valued at about $35,000. Finally, Coastal Bridge Advisors LLC acquired a new stake in shares of Cellectar Biosciences in the fourth quarter valued at about $64,000. 16.41% of the stock is currently owned by institutional investors.

About Cellectar Biosciences

(Get Free Report)

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer.

Further Reading

Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.